Abstract
Background Red blood cell distribution width (RDW), a routine indicator of erythrocyte volume variability, has shown potential in recent years in the prognostic assessment of a variety of diseases, including acute heart failure (AHF). The predictive ability of RDW-derived indices, namely the hemoglobin-to-RDW ratio (HRR), the RDW-to-lymphocyte ratio (RLR), the RDW-to-platelet ratio (RPR), the RDW-to-albumin ratio (RAR), and the product of RDW and mean corpuscular volume (RDW×MCV), for the prognosis of AHF remains unclear.
Methods The study included 4090 eligible patients in the MIMIC 3.0 database, screened variables using Lasso regression, assessed whether these derivatives independently predicted 1-year mortality from AHF by Cox proportional hazards model, and plotted survival curves and time-related ROC curves. Finally, the relationship between each indicator and outcome was analyzed by restricted cubic spline.
Results Positive events occurred in 2085 (51%) patients with decreased HRR and increased RLR, RPR, RAR, and RDW×MCV (P<0.001).After Cox model adjustment, HRR, RPR, RAR, and RDW×MCV remained independent predictors of 1-year prognosis for AHF (RLR was not) and the relationship may be more linear. Of these, RPR had the greatest impact on survival time (HR = 1.89, 95%CI: 1.33-2.67) and RDW×MCV had the highest predictive efficacy (AUC=0.612).
Conclusion RDW-derived indices HRR, RPR, RAR and RDW×MCV independently predicted 1-year mortality in AHF, and RLR had no independent predictive value.
Competing Interest Statement
The authors have declared that no competing interests exist.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
none
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos